TARO PHARMACEUTICAL INDUS (TARO)

IL0010827181 - Common Stock

42.2  -0.03 (-0.07%)

Full estimates are only available for subscribed users, you can see which data is available below.

Examples of complete estimate data are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional estimates and surprises .

Yearly Revenue, EBIT, EBITDA and EPS Analyst Estimates
2021 2022 2023 2024
Revenue
YoY % growth
549M
-14.86%		561.3M
2.24%		573M
2.08%		630.43M
10.02%
EBITDA
YoY % growth
168.8M
-36.99%		150.9M
-10.60%		49.8M
-67.00%		N/A
EBIT
YoY % growth
145.1M
-41.14%		125M
-13.85%		17.7M
-85.84%		-1.266M
-107.15%
Operating Margin
26.43%22.27%3.09%-0.20%
EPS
YoY % growth
-10.11
-258.96%		3.18
131.45%		0.67
-78.93%		1.12
67.46%

All data in USD

Quarterly Revenue, EBIT, EBITDA and EPS Analyst Estimates
Q4 / 24
EPS
Q2Q % growth		0.32
75.67%
Revenue
Q2Q % growth		159.18M
8.58%
EBITDA
Q2Q % growth		N/A
EBIT
Q2Q % growth		928.2K
-90.02%

All data in USD

Recent Earnings VS Estimates Surprises (USD)
PeriodReportedEstimateDifferenceSurprise
Q3 2024
Q2Q % growth		 0.54
184.21%		0.310.2376.47%
Q2 2024
Q2Q % growth		 0.38
642.86%		0.180.20106.97%
Q1 2024
Q2Q % growth		 0.40
8.11%		0.320.0826.50%
Q4 2023
Q2Q % growth		 0.18
-75.34%		0.23-0.05-23.27%
Recent Revenue VS Estimates Surprises (USD)
PeriodReportedEstimateDifferenceSurprise
Q3 2024
Q2Q % growth		 157.145M
12.89%		158.01M-865K-0.55%
Q2 2024
Q2Q % growth		 148.2M
13.56%		164.36M-16.16M-9.83%
Q1 2024
Q2Q % growth		 158.9M
1.40%		152.01M6.89M4.53%
Q4 2023
Q2Q % growth		 146.6M
2.30%		153.71M-7.11M-4.63%
EPS and Revenue Revisions
Next Q (1 month) Next Q (3 month) Next Year (1 month) Next Year (3 month)
EPS0% 0% 0% 0%
Revenue0% 0% 0% 0%